Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Research Progress in Nanopharmaceuticals with Different Delivery Routes in the Antivirus Field

Author(s): Yenong Shi, Dongqiong He, Xianwei Zhang, Mingqing Yuan* and Xu Liu*

Volume 29, Issue 25, 2023

Published on: 12 September, 2023

Page: [1975 - 1991] Pages: 17

DOI: 10.2174/1381612829666230830105817

Price: $65

Abstract

Human health is significantly threatened by infectious diseases caused by viral infection. Over the years, there have been numerous virus epidemics worldwide, causing millions of deaths. Traditional antiviral medications have many problems, including poor solubility and antiviral resistance. Additionally, because different drug delivery methods have different biological barriers to overcome, the drug’s bioavailability will be significantly affected. Therefore, it is essential that researchers create more effective antiviral drugs. To serve as a guide for the future development of nanosized antiviral drugs with stronger and more precise therapeutic effects, research has been performed on nanotechnology in the field of antiviral therapy. This review summarizes the recent developments in antiviral nanopharmaceuticals with different delivery routes. Research on 7 typical viruses, including COVID-19, has been included in this review. After being loaded into nanoparticles, antiviral drugs can be delivered through several drug modes of delivery, overcoming biological barriers. Moreover, some nanoparticles themselves have the ability to combat infections, so they can be used in conjunction with antiviral medication. The use of nanoparticle medications through various routes of administration can result in their unique benefits. They can be capable of overcoming its limitations as well as retaining the advantages of this method of delivery. This will motivate researchers to conducted a new investigation on nanoparticle medicines from the standpoint of the route of administration in order to increase the practicability of antiviral medications.

Keywords: Viral infection, antiviral drugs, nanotechnology, drug delivery route, vaccine, nanopharmaceuticals.

« Previous Next »
[1]
Waterer G, Bennett L. Control measures for human respiratory viral infection. Semin Respir Crit Care Med 2016; 37(4): 631-9.
[http://dx.doi.org/10.1055/s-0036-1584792] [PMID: 27486741]
[2]
Hokello J, Sharma AL, Tyagi M. An update on the HIV DNA vaccine strategy. Vaccines 2021; 9(6): 605.
[http://dx.doi.org/10.3390/vaccines9060605] [PMID: 34198789]
[3]
Nayagam S, Chan P, Zhao K, et al. Investment case for a comprehensive package of interventions against hepatitis B in China: Applied modeling to help national strategy planning. Clin Infect Dis 2021; 72(5): 743-52.
[http://dx.doi.org/10.1093/cid/ciaa134] [PMID: 32255486]
[4]
Morens DM, Fauci AS. Emerging pandemic diseases: How we got to COVID-19. Cell 2020; 182(5): 1077-92.
[http://dx.doi.org/10.1016/j.cell.2020.08.021] [PMID: 32846157]
[5]
World health statistics 2022: Monitoring health for the SDGs, sustainable development goals. World Health Organization 2022.
[6]
Ahmadzadeh J, Mobaraki K, Mousavi SJ, Aghazadeh-Attari J, Mirza-Aghazadeh-Attari M, Mohebbi I. The risk factors associated with MERS-CoV patient fatality: A global survey. Diagn Microbiol Infect Dis 2020; 96(3): 114876.
[http://dx.doi.org/10.1016/j.diagmicrobio.2019.114876] [PMID: 31959375]
[7]
Draz MS, Shafiee H. Applications of gold nanoparticles in virus detection. Theranostics 2018; 8(7): 1985-2017.
[http://dx.doi.org/10.7150/thno.23856] [PMID: 29556369]
[8]
Eisenreich W, Rudel T, Heesemann J, Goebel W. How viral and intracellular bacterial pathogens reprogram the metabolism of host cells to allow their intracellular replication. Front Cell Infect Microbiol 2019; 9: 42.
[http://dx.doi.org/10.3389/fcimb.2019.00042] [PMID: 30886834]
[9]
Gruenberg J. Viruses and endosome membrane dynamics. Curr Opin Cell Biol 2009; 21(4): 582-8.
[http://dx.doi.org/10.1016/j.ceb.2009.03.008] [PMID: 19443190]
[10]
De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 2016; 29(3): 695-747.
[http://dx.doi.org/10.1128/CMR.00102-15] [PMID: 27281742]
[11]
Saurabh S, Mahavir BC, Arun KK, et al. Nanomedicine based approaches for combating viral infections. J Control Release 2021; 338: 80-104.
[12]
Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49(S5): S185-95.
[http://dx.doi.org/10.1002/hep.22885] [PMID: 19399802]
[13]
Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res 2021; 11(3): 748-87.
[http://dx.doi.org/10.1007/s13346-020-00818-0] [PMID: 32748035]
[14]
Delshadi R, Bahrami A, McClements DJ, Moore MD, Williams L. Development of nanoparticle-delivery systems for antiviral agents: A review. J Control Release 2021; 331(10): 30-44.
[http://dx.doi.org/10.1016/j.jconrel.2021.01.017] [PMID: 33450319]
[15]
Muhammad W, Zhai Z, Gao C. Antiviral activity of nanomaterials against coronaviruses. Macromol Biosci 2020; 20(10): 2000196.
[http://dx.doi.org/10.1002/mabi.202000196] [PMID: 32783352]
[16]
Prabhakara C, Godbole R, Sil P. Niclosamide inhibits SARS- CoV-2 entry by blocking internalization through pH-dependent CLIC/GEEC endocytic pathway. Cold Spring Harbor Laboratory 2020.
[http://dx.doi.org/10.1101/2020.12.16.422529]
[17]
Hobson JJ, Savage AC, Dwyer AB, et al. Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale 2021; 13(13): 6410-6.
[http://dx.doi.org/10.1039/D1NR00309G] [PMID: 33885522]
[18]
Rejinold N S, Choi G, Piao H, Choy JH. Bovine serum albumin- coated niclosamide-zein nanoparticles as potential injectable medicine against COVID-19. Materials 2021; 14(14): 3792-2.
[http://dx.doi.org/10.3390/ma14143792] [PMID: 34300711]
[19]
Wang W, Smith N, Makarov E, et al. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine 2020; 28: 102185.
[http://dx.doi.org/10.1016/j.nano.2020.102185] [PMID: 32217146]
[20]
Hobson JJ, Al-khouja A, Curley P, et al. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nat Commun 2019; 10(1): 1413.
[http://dx.doi.org/10.1038/s41467-019-09354-z] [PMID: 30926773]
[21]
Tanaudommongkon I, Tanaudommongkon A, Dong X. Development of in situ self-assembly nanoparticles to encapsulate lopinavir and ritonavir for long-acting subcutaneous injection. Pharmaceutics 2021; 13(6): 904-4.
[http://dx.doi.org/10.3390/pharmaceutics13060904] [PMID: 34207272]
[22]
Homayun B, Lin X, Choi HJ. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics 2019; 11(3): 129.
[http://dx.doi.org/10.3390/pharmaceutics11030129] [PMID: 30893852]
[23]
Rejinold NS, Piao H, Choi G, Jin GW, Choy JH. Niclosamide-exfoliated anionic clay nano hybrid repurposed as an antiviral drug for tackling COVID-19; oral formulation with tween 60/eudragitS100. Clays Clay Miner 2021; 69(5): 533-46.
[http://dx.doi.org/10.1007/s42860-021-00153-6] [PMID: 34785820]
[24]
Choi G, Piao H, Rejinold NS, et al. Hydrotalcite-niclosamide nanohybrid as oral formulation towards SARS-CoV-2 viral infections. Pharmaceuticals 2021; 14(5): 486-6.
[http://dx.doi.org/10.3390/ph14050486] [PMID: 34069716]
[25]
Surnar B, Kamran MZ, Shah AS, Dhar S. Clinically approved antiviral drug in an orally administrable nanoparticle for COVID-19. ACS Pharmacol Transl Sci 2020; 3(6): 1371-80.
[http://dx.doi.org/10.1021/acsptsci.0c00179] [PMID: 33330844]
[26]
Surnar B, Kamran MZ, Shah AS, et al. Orally administrable therapeutic synthetic nanoparticle for zika virus. ACS Nano 2019; 13(10): 11034-48.
[http://dx.doi.org/10.1021/acsnano.9b02807] [PMID: 31603314]
[27]
Li K, McCray PB Jr. Development of a mouse-adapted MERS coronavirus. Methods Mol Biol 2020; 2099: 161-71.
[http://dx.doi.org/10.1007/978-1-0716-0211-9_13] [PMID: 31883095]
[28]
Mrityunjaya M, Pavithra V, Neelam R, Janhavi P, Halami PM, Ravindra PV. Immune-boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19. Front Immunol 2020; 11: 570122-2.
[http://dx.doi.org/10.3389/fimmu.2020.570122] [PMID: 33117359]
[29]
Zakaria MY, Fayad E, Althobaiti F, Zaki I, Abu Almaaty AH. Statistical optimization of bile salt deployed nanovesicles as a potential platform for oral delivery of piperine: Accentuated antiviral and anti-inflammatory activity in MERS-CoV challenged mice. Drug Deliv 2021; 28(1): 1150-65.
[http://dx.doi.org/10.1080/10717544.2021.1934190] [PMID: 34121561]
[30]
Zakaria MY, Georghiou PE, Banoub JH, Beshay BY. Inclusion of a phytomedicinal flavonoid in biocompatible surface-modified chylomicron mimic nanovesicles with improved oral bioavailability and virucidal activity: Molecular modeling and pharmacodynamic studies. Pharmaceutics 2022; 14(5): 905-5.
[http://dx.doi.org/10.3390/pharmaceutics14050905] [PMID: 35631491]
[31]
Krieser K, Emanuelli J, Daudt RM, et al. Taste-masked nanoparticles containing Saquinavir for pediatric oral administration. Mater Sci Eng C 2020; 117: 111315-5.
[http://dx.doi.org/10.1016/j.msec.2020.111315] [PMID: 32919675]
[32]
Islam MS, Reineke J, Kaushik R, et al. Bioadhesive food protein nanoparticles as pediatric oral drug delivery system. ACS Appl Mater Interfaces 2019; 11(20): 18062-73.
[http://dx.doi.org/10.1021/acsami.9b00152] [PMID: 31033278]
[33]
Singh Chauhan P, Abutbul Ionita I, Moshe Halamish H, Sosnik A, Danino D. Multidomain drug delivery systems of β-casein micelles for the local oral co-administration of antiretroviral combinations. J Colloid Interface Sci 2021; 592(15): 156-66.
[http://dx.doi.org/10.1016/j.jcis.2020.12.021] [PMID: 33652169]
[34]
Thandi CS, Whittam L. Diagnosis and management of common viral skin infections. Prescriber 2021; 32(4): 10-4.
[http://dx.doi.org/10.1002/psb.1907]
[35]
Ali AM, Hill HJ, Elkhouly GE, et al. Rhamnolipid nano-micelles inhibit SARS-CoV-2 infection and have no dermal or eye toxic effects in rabbits. Antibiotics 2022; 11(11): 1556.
[http://dx.doi.org/10.3390/antibiotics11111556] [PMID: 36358211]
[36]
H Ali A, A Alheety M, Hasen AM, Dohare S. Nano drug (AgNPs capped with hydroxychloroquine): Synthesis, characterization, anti-COVID-19 and healing the wound infected with S. aureus. Mater Chem Phys 2022; 287: 126249-9.
[http://dx.doi.org/10.1016/j.matchemphys.2022.126249] [PMID: 35581994]
[37]
Serrano-Aroca Á, Takayama K, Tuñón-Molina A, et al. Carbon-based nanomaterials: Promising antiviral agents to combat COVID-19 in the microbial-resistant era. ACS Nano 2021; 15(5): 8069-86.
[http://dx.doi.org/10.1021/acsnano.1c00629] [PMID: 33826850]
[38]
Serrano-Aroca Á, Ferrandis-Montesinos M, Wang R. Antiviral properties of alginate-based biomaterials: Promising antiviral agents against SARS-CoV-2. ACS Appl Bio Mater 2021; 4(8): 5897-907.
[http://dx.doi.org/10.1021/acsabm.1c00523] [PMID: 35006918]
[39]
Cano-Vicent A, Hashimoto R, Takayama K, Serrano-Aroca Á. Biocompatible films of calcium alginate inactivate enveloped viruses such as SARS-CoV-2. Polymers 2022; 14(7): 1483-3.
[http://dx.doi.org/10.3390/polym14071483] [PMID: 35406356]
[40]
Alejandro H, Alba CV, Alberto TM, et al. Engineering alginate hydrogel films with poly and graphene Nano platelets: Enhancement of antiviral activity, cell adhesion and electroactive properties. Int J Biol Macromol 2022; 219: 694-708.
[http://dx.doi.org/10.1016/j.ijbiomac.2022.08.039] [PMID: 35961550]
[41]
Zsikó S, Csányi E, Kovács A, Budai-Szűcs M, Gácsi A, Berkó S. Methods to evaluate skin penetration in vitro. Sci Pharm 2019; 87(3): 19.
[http://dx.doi.org/10.3390/scipharm87030019]
[42]
Lee JS, Oh H, Kim S, Lee JH, Shin YC, Choi WI. A novel chitosan nanosponge as a vehicle for transepidermal drug delivery. Pharmaceutics 2021; 13(9): 1329.
[http://dx.doi.org/10.3390/pharmaceutics13091329] [PMID: 34575405]
[43]
Giacobbe DR, Di Bella S, Lovecchio A, et al. Herpes simplex virus 1 (HSV-1) reactivation in critically Ill COVID-19 patients: A brief narrative review. Infect Dis Ther 2022; 11(5): 1779-91.
[http://dx.doi.org/10.1007/s40121-022-00674-0] [PMID: 35913679]
[44]
Al-Subaie MM, Hosny KM, El-Say KM, Ahmed TA, Aljaeid BM. Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections. Int J Nanomedicine 2015; 10: 3973-85.
[PMID: 26109856]
[45]
Abd-Elsalam WH, Ibrahim RR. Span 80/TPGS modified lipid- coated chitosan nanocomplexes of acyclovir as a topical delivery system for viral skin infections. Int J Pharm 2021; 609: 121214-4.
[http://dx.doi.org/10.1016/j.ijpharm.2021.121214] [PMID: 34678396]
[46]
Wadhawan J, Parmar PK, Bansal AK. Nanocrystals for improved topical delivery of medium soluble drug: A case study of acyclovir. J Drug Deliv Sci Technol 2021; 65: 102662.
[http://dx.doi.org/10.1016/j.jddst.2021.102662]
[47]
Almehmady AM, Ali SA. Transdermal film loaded with garlic oil-acyclovir nanoemulsion to overcome barriers for its use in alleviating cold sore conditions. Pharmaceutics 2021; 13(5): 669.
[http://dx.doi.org/10.3390/pharmaceutics13050669] [PMID: 34066923]
[48]
Kazsoki A, Palcsó B, Alpár A, Snoeck R, Andrei G, Zelkó R. Formulation of acyclovir (core)-dexpanthenol (sheath) nanofibrous patches for the treatment of herpes labialis. Int J Pharm 2022; 611: 121354-4.
[http://dx.doi.org/10.1016/j.ijpharm.2021.121354] [PMID: 34883208]
[49]
Annaji M, Mita N, Rangari S, et al. Enhanced topical co-delivery of acyclovir and lidocaine gel formulation across dermatomed human skin. AAPS PharmSciTech 2022; 23(8): 305.
[http://dx.doi.org/10.1208/s12249-022-02458-8] [PMID: 36401127]
[50]
Abrantes DC, Rogerio CB, Campos EVR, et al. Repellent active ingredients encapsulated in polymeric nanoparticles: Potential alternative formulations to control arboviruses. J Nanobiotechnol 2022; 20: 520.
[51]
Gao Y, Zhang W, Cheng YF, et al. Intradermal administration of green synthesized nanosilver (NS) through film-coated PEGDA microneedles for potential antibacterial applications. Biomater Sci 2021; 9(6): 2244-54.
[http://dx.doi.org/10.1039/D0BM02136A] [PMID: 33514957]
[52]
Gipson IK, Argüeso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol 2003; 231: 1-49.
[http://dx.doi.org/10.1016/S0074-7696(03)31001-0] [PMID: 14713002]
[53]
Huang XN, Huang YJ, Shao DP. The impact of SARS-CoV-2 on the eyes and its possibility of transmission through the eye pathway. Adv Ophthalmol Optom 2021; 41(10): 996-1000.
[54]
Wang X, Chen L, Wang X, et al. Long-acting protective ocular surface by instilling adhesive dual-antiviral nanoparticles. Adv Healthc Mater 2022; 11(14): 2200283.
[http://dx.doi.org/10.1002/adhm.202200283] [PMID: 35579101]
[55]
Chen L, Wu F, Pang Y, et al. Therapeutic nanocoating of ocular surface. Nano Today 2021; 41: 101309. [J
[http://dx.doi.org/10.1016/j.nantod.2021.101309]
[56]
Guo Q, Jia L, Qinggeletu , Zhang R, Yang X. In vitro and in vivo evaluation of ketotifen-gold nanoparticles laden contact lens for controlled drug delivery to manage conjunctivitis. J Drug Deliv Sci Technol 2021; 64: 102538.
[http://dx.doi.org/10.1016/j.jddst.2021.102538]
[57]
Das Jana I, Kumbhakar P, Banerjee S, et al. Copper nanoparticle- graphene composite-based transparent surface coating with antiviral activity against influenza virus. ACS Appl Nano Mater 2021; 4(1): 352-62.
[http://dx.doi.org/10.1021/acsanm.0c02713]
[58]
Cano-Vicent A, Tuñón-Molina A, Martí M, et al. Antiviral face mask functionalized with solidified hand soap: Low-cost infection prevention clothing against enveloped viruses such as SARS- CoV-2. ACS Omega 2021; 6(36): 23495-503.
[http://dx.doi.org/10.1021/acsomega.1c03511] [PMID: 34514272]
[59]
Colnago LA, Trevisol IM, Voss Rech D, et al. Simple, low-cost and long-lasting film for virus inactivation using avian coronavirus model as challenge. Int J Environ Res Public Health 2020; 17(18): 6456-6.
[http://dx.doi.org/10.3390/ijerph17186456] [PMID: 32899803]
[60]
Lin Z, Wang Z, Zhang X, Diao D. Superhydrophobic, photo-sterilize, and reusable mask based on graphene nanosheet-embedded carbon (GNEC) film. Nano Res 2021; 14(4): 1110-5.
[http://dx.doi.org/10.1007/s12274-020-3158-1] [PMID: 33250970]
[61]
Lee J, Bae J, Youn DY, et al. Violacein-embedded nanofiber filters with antiviral and antibacterial activities. Chem Eng J 2022; 444: 136460.
[http://dx.doi.org/10.1016/j.cej.2022.136460] [PMID: 35463870]
[62]
Parra-Ortiz E, Malmsten M. Photocatalytic nanoparticles – From membrane interactions to antimicrobial and antiviral effects. Adv Colloid Interface Sci 2022; 299: 102526.
[http://dx.doi.org/10.1016/j.cis.2021.102526] [PMID: 34610862]
[63]
Di Mauro A, Zimbone M, Fragalà ME, Impellizzeri G. Synthesis of ZnO nanofibers by the electrospinning process. Mater Sci Semicond Process 2016; 42: 98-101.
[http://dx.doi.org/10.1016/j.mssp.2015.08.003]
[64]
Yoon J, Kim J, Park S, Jeong YW, Lee C, Oh SG. Fabrication of Ag-doped ZnO/PAN composite nanofibers by electrospinning: Photocatalytic and antiviral activities. Korean J Chem Eng 2022; 39(6): 1632-40.
[http://dx.doi.org/10.1007/s11814-021-1037-4] [PMID: 35125591]
[65]
Yoon J, Kim J, Lee J, et al. Fabrication of antiviral nanofibers containing various Cu salts and ZnO nanorods by electrospinning. J Ind Eng Chem 2022; 116: 572-80.
[http://dx.doi.org/10.1016/j.jiec.2022.09.045]
[66]
Amiri M, Eskandari K, Salavati-Niasari M. Magnetically retrievable ferrite nanoparticles in the catalysis application. Adv Colloid Interface Sci 2019; 271: 101982.
[http://dx.doi.org/10.1016/j.cis.2019.07.003] [PMID: 31325653]
[67]
Monsef R, Ghiyasiyan-Arani M, Salavati-Niasari M. Design of magnetically recyclable ternary Fe2O3/EuVO4/g-C3N4 nanocomposites for photocatalytic and electrochemical hydrogen storage. ACS Appl Energy Mater 2021; 4(1): 680-95. [J
[http://dx.doi.org/10.1021/acsaem.0c02557]
[68]
Monsef R, Ghiyasiyan-Arani M, Salavati-Niasari M. Application of ultrasound-aided method for the synthesis of NdVO4 nano-photocatalyst and investigation of eliminate dye in contaminant water. Ultrason Sonochem 2018; 42: 201-11.
[http://dx.doi.org/10.1016/j.ultsonch.2017.11.025] [PMID: 29429662]
[69]
Lee J, Kim KS, Na K. Intranasal administration of an aronia extract and carrageenan nanocomposite for the prevention of influenza A H1N1 virus infection. J Pharm Investig 2022; 52(6): 765-74.
[http://dx.doi.org/10.1007/s40005-022-00591-x]
[70]
Krzyzowska M, Chodkowski M, Janicka M, et al. Lactoferrin- functionalized noble metal nanoparticles as new antivirals for hsv-2 infection. Microorganisms 2022; 10(1): 110.
[http://dx.doi.org/10.3390/microorganisms10010110] [PMID: 35056558]
[71]
Patki M, Vartak R, Jablonski J, et al. Efavirenz nanomicelles loaded vaginal film (EZ film) for preexposure prophylaxis (PrEP) of HIV. Colloids Surf B Biointerfaces 2020; 194: 111174.
[http://dx.doi.org/10.1016/j.colsurfb.2020.111174] [PMID: 32540766]
[72]
Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin- expressing plasmid DNA. Vaccine 1993; 11(9): 957-60.
[http://dx.doi.org/10.1016/0264-410X(93)90385-B] [PMID: 8212843]
[73]
Pan J, Cui Z. Self-assembled nanoparticles: Exciting platforms for vaccination. Biotechnol J 2020; 15(12): 2000087.
[http://dx.doi.org/10.1002/biot.202000087] [PMID: 33411412]
[74]
Wu F, Qin M, Wang H, Sun X. Nanovaccines to combat virus-related diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2023; 15(2): e1857-7.
[http://dx.doi.org/10.1002/wnan.1857] [PMID: 36184873]
[75]
Zhang YQ, Sun YP, Qi JX. Research progress in antiviral nanoparticle vaccines. Prog Pharm 2022; 46(10): 751-60.
[76]
Roth GA, Picece VCTM, Ou BS, Luo W, Pulendran B, Appel EA. Designing spatial and temporal control of vaccine responses. Nat Rev Mater 2021; 7(3): 174-95.
[http://dx.doi.org/10.1038/s41578-021-00372-2] [PMID: 34603749]
[77]
kheirollahpour M, Mehrabi M, Dounighi NM, Mohammadi M, Masoudi A. Nanoparticles and vaccine development. Pharm Nanotechnol 2020; 8(1): 6-21.
[http://dx.doi.org/10.2174/2211738507666191024162042] [PMID: 31647394]
[78]
Vu MN, Kelly HG, Kent SJ, Wheatley AK. Current and future nanoparticle vaccines for COVID-19. EBioMedicine 2021; 74: 103699.
[http://dx.doi.org/10.1016/j.ebiom.2021.103699] [PMID: 34801965]
[79]
Rojas-Sánchez L, Zhang E, Sokolova V, et al. Genetic immunization against hepatitis B virus with calcium phosphate nanoparticles in vitro and in vivo. Acta Biomater 2020; 110: 254-65.
[http://dx.doi.org/10.1016/j.actbio.2020.04.021] [PMID: 32344172]
[80]
Qiao D, Chen Y, Liu L. Engineered therapeutic nanovaccine against chronic hepatitis B virus infection. Biomaterials 2021; 269: 120674.
[http://dx.doi.org/10.1016/j.biomaterials.2021.120674] [PMID: 33486345]
[81]
Screaton G, Mongkolsapaya J. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? Cold Spring Harb Perspect Biol 2018; 10(6): a029520.
[http://dx.doi.org/10.1101/cshperspect.a029520] [PMID: 28716884]
[82]
Sharma M, Glasner DR, Watkins H, et al. Magnitude and functionality of the NS1-specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate. J Infect Dis 2020; 221(6): 867-77.
[http://dx.doi.org/10.1093/infdis/jiz081] [PMID: 30783676]
[83]
He L, Sun W, Yang L, Liu W, Li J. A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi- serotype DENV in mice. Virol Sin 2022; 37(5): 746-57.
[http://dx.doi.org/10.1016/j.virs.2022.07.003] [PMID: 35835315]
[84]
Wollner CJ, Richner M, Hassert MA, Pinto AK, Brien JD, Richner JM. A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses. J Virol 2021; 95(12): e02482-20.
[http://dx.doi.org/10.1128/JVI.02482-20] [PMID: 33762420]
[85]
Nayak V, Singh KRB, Singh AK, Singh RP. Potentialities of selenium nanoparticles in biomedical science. New J Chem 2021; 45(6): 2849-78.
[http://dx.doi.org/10.1039/D0NJ05884J]
[86]
Liu X, Chen D, Su J, et al. Selenium nanoparticles inhibited H1N1 influenza virus-induced apoptosis by ROS-mediated signaling pathways. RSC Adv 2022; 12(7): 3862-70.
[http://dx.doi.org/10.1039/D1RA08658H] [PMID: 35425430]
[87]
Tang Z, Zhang X, Shu Y, Guo M, Zhang H, Tao W. Insights from nanotechnology in COVID-19 treatment. Nano Today 2021; 36: 101019.
[http://dx.doi.org/10.1016/j.nantod.2020.101019] [PMID: 33178330]
[88]
Wang C, Beiss V, Steinmetz NF. Cowpea mosaic virus nanoparticles and empty virus-like particles show distinct but overlapping immunostimulatory properties. J Virol 2019; 93(21): e00129-19.
[http://dx.doi.org/10.1128/JVI.00129-19] [PMID: 31375592]
[89]
Nkanga CI, Ortega-Rivera OA, Shin MD, Moreno-Gonzalez MA, Steinmetz NF. Injectable slow-release hydrogel formulation of a plant virus-based COVID-19 vaccine candidate. Biomacromolecules 2022; 23(4): 1812-25.
[http://dx.doi.org/10.1021/acs.biomac.2c00112] [PMID: 35344365]
[90]
Geng Q, Tai W, Baxter VK, et al. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. PLoS Pathog 2021; 17(9): e1009897.
[http://dx.doi.org/10.1371/journal.ppat.1009897] [PMID: 34492082]
[91]
Joyce MG, King H A D, Naouar IE, et al. Efficacy of a broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine in nonhuman primates bioRxiv 2021; 436523.
[http://dx.doi.org/10.1101/2021.03.24.436523]
[92]
da Rocha Dias S, Salmonson T, van Zwieten-Boot B, et al. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2013; 49(7): 1654-61.
[http://dx.doi.org/10.1016/j.ejca.2013.01.015] [PMID: 23481513]
[93]
Abduljauwad SN, Habib T, Ahmed HR. Nano-clays as potential pseudo-antibodies for COVID-19. Nanoscale Res Lett 2020; 15(1): 173-3.
[http://dx.doi.org/10.1186/s11671-020-03403-z] [PMID: 32857226]
[94]
Ou BS, Picece VC, Baillet J, et al. Nanoparticle-conjugated TLR9 agonists improve the potency, durability, and breadth of COVID-19 vaccines bioRxiv 2023; 522505.
[http://dx.doi.org/10.1101/2023.01.02.522505]
[95]
Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384(15): 1412-23.
[http://dx.doi.org/10.1056/NEJMoa2101765] [PMID: 33626250]
[96]
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384(5): 403-16.
[http://dx.doi.org/10.1056/NEJMoa2035389] [PMID: 33378609]
[97]
Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020; 383(24): 2320-32.
[http://dx.doi.org/10.1056/NEJMoa2026920] [PMID: 32877576]
[98]
Yin Y, Su W, Zhang J, et al. Separable microneedle patch to protect and deliver DNA nanovaccines against COVID-19. ACS Nano 2021; 15(9): 14347-59.
[http://dx.doi.org/10.1021/acsnano.1c03252] [PMID: 34472328]
[99]
Peng KW, Carey T, Lech P, et al. Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine. Vaccine 2022; 40(15): 2342-51.
[http://dx.doi.org/10.1016/j.vaccine.2021.12.063] [PMID: 35282925]
[100]
Vaca GB, Meyer M, Cadete A, et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection bioRxiv 2023; 523616.
[http://dx.doi.org/10.1101/2023.01.11.523616]
[101]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[102]
Wolfram J, Zhu M, Yang Y, et al. Safety of nanoparticles in medicine. Curr Drug Targets 2015; 16(14): 1671-81.
[http://dx.doi.org/10.2174/1389450115666140804124808] [PMID: 26601723]
[103]
Gispert I. Overview of nanomedicines regulation in the European union. Front Nanosci 2012; 4: 487-507.
[http://dx.doi.org/10.1016/B978-0-12-415769-9.00016-9]
[104]
Isles MP. Nanomedicines and nanosimilars-why a robust centralised regulatory framework is essential to enhance patient safety. Front Pharmacol 2022; 12: 787239-9.
[http://dx.doi.org/10.3389/fphar.2021.787239] [PMID: 35280250]
[105]
Tyner KM, Zheng N, Choi S, et al. How has CDER prepared for the nano revolution? a review of risk assessment, regulatory research, and guidance activities. AAPS J 2017; 19(4): 1071-83.
[http://dx.doi.org/10.1208/s12248-017-0084-6] [PMID: 28421428]
[106]
Wang GY. Regulatory perspective of the CMC considerations for nanodrug development. Chin Pharm J 2019; 50(10): 1215-27.
[107]
Monsef R, Salavati-Niasari M. Electrochemical sensor based on a chitosan-molybdenum vanadate nanocomposite for detection of hydroxychloroquine in biological samples. J Colloid Interface Sci 2022; 613: 1-14.
[http://dx.doi.org/10.1016/j.jcis.2022.01.039] [PMID: 35030412]
[108]
Monsef R, Salavati-Niasari M. Hydrothermal architecture of Cu5V2O10 nanostructures as new electro-sensing catalysts for voltammetric quantification of mefenamic acid in pharmaceuticals and biological samples. Biosens Bioelectron 2021; 178: 113017-7.
[http://dx.doi.org/10.1016/j.bios.2021.113017] [PMID: 33493895]
[109]
Kowah JAH, Gao R, Li F, et al. Matrine family derivatives: Synthesis, reactions procedures, mechanism, and application in medicinal, agricultural, and materials chemistry. Eur J Med Chem Rep 2023; 7: 100098.
[http://dx.doi.org/10.1016/j.ejmcr.2022.100098]

Rights & Permissions Print Cite
Article Metrics
19
2
© 2024 Bentham Science Publishers | Privacy Policy